Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

CDK6: a potential drug target for severe COVID-19

Researchers identify a methodology and workflow to repurpose drugs against the cyclin-dependent kinase 6 target gene of SARS-CoV-2.

27 Mar 2022

Researchers investigate Galectin-9 as a new treatment target for COVID-19

Researchers discuss alternate therapeutic targets for treating COVID-19 and the effects of Gal-9 on SARS-CoV-2 infection and the immune response.

23 Mar 2022

Study reveals new opportunities for using small molecule drugs to target KRAS mutants

Research published today in Nature Chemical Biology reveals new opportunities for using small molecule drugs to target KRAS, the most commonly mutated protein in cancer.

23 Mar 2022

Powerful tool to monitor membrane proteins trafficking for drug discovery

Inside your body on the surface of cell membranes, a metaphorical communication and traffic network is underway as hormones - or chemical messengers - bind to cell membrane receptors to fine tune how the cell behaves.

22 Mar 2022

CD63-expressing extracellular vesicles neutralize SARS-CoV-2 variants of concern

Researchers evaluate antiviral effects of CD63 tetraspanin extracellular vesicles against SARS-CoV-2 and HIV-1.

22 Mar 2022

The obstacles to developing high-throughput 3D wound healing models

In this interview, News-Medical talks to Dr. Glauco Souza and Linda Boekestijn about their work in the wound healing space and how they devised a new high throughput 3D model for would healing.

From PromoCell 22 Mar 2022

Oral drug that reverses immune aging effectively prevents death in COVID-19 mouse model

The immune system deteriorates with age, making COVID-19 particularly deadly in older people -; but to date, no clinically available medication addresses this key risk factor.

21 Mar 2022

Study unveils several natural marine products as potential agents against SARS-CoV-2

A recent study, published in the Journal of Natural Products of the American Chemical Society and American Society of Pharmacognosy, highlighted three natural marine products as potent inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – without any apparent toxic effects for human lung cells.

21 Mar 2022

Optical coherence tomography reveals the beating and development of human heart organoids

Researchers have been using organoids -; 3D organ-like, tightly-packed cell cultures -; as models to study organ development, disease and drug discovery with excellent success.

16 Mar 2022

Acacetin shows potency against SARS-CoV-2 spike protein

Researchers use molecular docking to screen phytocompounds and evaluate their binding affinity with SARS-CoV-2.

15 Mar 2022

Mason scientists receive DOD funding for breast cancer prevention and treatment research

George Mason University College of Science announced a $1.57 million dollar grant from the Department of Defense to fund a transformative approach for breast cancer treatment developed by scientists in Mason's Center for Drug Discovery for Rare Diseases.

15 Mar 2022

New smartphone app can calculate users’ genetic risk for coronary artery disease

A Scripps Research team developed a smartphone app that can calculate users' genetic risk for coronary artery disease (CAD)-; and found that users at high risk sought out appropriate medication after using the app.

14 Mar 2022

Canadian scientist discusses about how society could better prepare for future pandemics

Aled Edwards is of two minds about medicine's response to COVID-19. On one hand, he notes, we had life-saving vaccines and therapies less than a year after the discovery of SARS-CoV-2. On the other, more than six million, and possibly as many as 18 million people have died, and global access to advances that can prevent and treat severe disease remains highly inequitable.

11 Mar 2022

Further optimization of cysteine-reactive pyrazoline-based covalent inhibitors for the SARS-CoV-2 Mpro

Researchers discovered and optimized cysteine-reactive pyrazoline-based covalent inhibitors for several coronaviruses' Mpro, including SARS-CoV-2.

11 Mar 2022

COVID-19 and the life sciences; what have we learned and where are we going?

News-Medical attended the 2022 SLAS press briefing where Peter Simpson, Michael Girardi, and Simon Meffan-Main gave their thoughts on the life sciences sector post-COVID-19.

From Society for Laboratory Automation and Screening (SLAS) 4 Mar 2022

Novel drug candidate protects lab mice against cognitive decline by reducing brain inflammation

An anti-inflammatory drug candidate, known as 3,6'-dithiopomalidomide (DP), designed by researchers at the National Institute on Aging, protected lab mice against cognitive decline by reducing brain inflammation.

2 Mar 2022

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

A new study describes the efficacy of adenosine receptor agonists in the treatment of SARS-CoV-2 infection.

2 Mar 2022

Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software

Optibrium Ltd, a leading developer of software for drug discovery, today announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation, and data analysis.

From Optibrium Ltd. 2 Mar 2022

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that it has dosed multiple healthy volunteers in Phase I clinical trial evaluating ISM001-055, the first anti-fibrotic small molecule inhibitor generated by Insilico's AI-powered drug discovery platform for idiopathic pulmonary fibrosis (IPF).

24 Feb 2022

Semarion raises £2.14 million GBP ($2.89 million USD) seed funding

Investors include Parkwalk Advisors, University of Cambridge Seed Funds, Martlet Capital, and angel investors.

From Semarion 24 Feb 2022